Exelixis gains
Zacks.com on MSN3h
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...
Wells Fargo analyst Derek Archila maintained a Buy rating on Exelixis (EXEL – Research Report) yesterday and set a price target of ...
"Exelixis and MSD to trial cancer therapies together in clinical collaboration" was originally created and published by ...
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday after Bank of America raised their price target on the stock from $30.00 to ...
Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...
In addition to the legal success, Exelixis has received an upgrade from B of A Securities. The firm has maintained a Buy rating and raised the price target from $30 to $32. This optimistic outlook ...
Zacks.com on MSN1d
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCCExelixis, Inc. EXEL entered into a clinical development collaboration agreement with pharma giant Merck MRK to advance the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback